J. Massó

发表

Mutations in Progranulin Gene: Clinical, Pathological, and Ribonucleic Acid Expression Findings

I. Ferrer, A. Sáenz, A. Gorostidi, 2008, Biological Psychiatry.

The Discovery of the Dardarin Gene 15 Years Later: A Globalized Local History.

A. L. Munain, J. Massó, J. Tur, 2020 .

Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain)

A. Gorostidi, J. Ruiz‐Martinez, A. L. de Munain, 2010, Movement disorders : official journal of the Movement Disorder Society.

Cabergoline in the treatment of early parkinson's disease

C. Marsden, J. Montastruc, R. Grimaldi, 1997, Neurology.

In Vitro and in Vivo Anti-Inflammatory Activity of the New Glucocorticoid Ciclesonide

R. Riedel, D. Bundschuh, A. Hatzelmann, 2004, Journal of Pharmacology and Experimental Therapeutics.

Modulation of inflammatory responses by diterpene acids from Helianthus annuus L.

S. Hortelano, N. Girón, B. de Las Heras, 2008, Biochemical and biophysical research communications.

The Long-Acting Dopamine Receptor Agonist Cabergoline in Early Parkinson’s Disease

J. Montastruc, F. Bracco, O. Gershanik, 2004, CNS drugs.

Distinctive age-related temporal cortical thinning in asymptomatic granulin gene mutation carriers

David Bartrés-Faz, Roser Sala-Llonch, Adolfo López de Munain, 2013, Neurobiology of Aging.

Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study

C. Paisán-Ruiz, A. Gorostidi, J. Ruiz‐Martinez, 2009, Movement disorders : official journal of the Movement Disorder Society.

Neurogenetic Disorders in the Basque Population

A. López de Munain, J. Zarranz, D. Otaegui, 2015, Annals of human genetics.

Parkin and LRRK2/Dardarin Mutations in Early Onset Parkinson's Disease in the Basque Country (Spain)

C. Paisán-Ruiz, A. Gorostidi, J. Ruiz‐Martinez, 2015 .

Parkin and LRRK 2 / Dardarin Mutations in Early Onset Parkinson ’ s Disease in the Basque Country ( Spain )

A. López de Munain, C. Paisán-Ruiz, A. Gorostidi, 2015 .

Power spectral distribution analysis for detection of freezing of gait in patients with Parkinson’s disease

Haritz Zabaleta, Thierry Keller, T. Keller, 2009 .

Relationship Between the Efficacy of Rivastigmine and Apolipoprotein E (ϵ4) in Patients With Mild to Moderately Severe Alzheimer Disease

M. Boada, R. Blesa, M. Aguilar, 2006, Alzheimer disease and associated disorders.

Familial amyloidosis with polyneuropathy type 1 caused by transthyretin mutation Val50Met (Val30Met): 4 cases in a non-endemic area

N. Andrés, J. Poza, J. M. Masso, 2018, Neurología (English Edition).

Prevalence of myotonic dystrophy in Guipúzcoa (Basque Country, Spain)

J. Emparanza, M. Baiget, A. L. de Munain, 1993, Neurology.

Limb-girdle muscular dystrophy in Guipúzcoa (Basque Country, Spain).

J. Beckmann, I. Richard, F. Leturcq, 1998, Brain : a journal of neurology.

Effect of Fepradinol on Rat Hind Paw Oedema Induced by Several Inflammatory Agents

Á. Villar, J. Massó, J. Conde, 1993, The Journal of pharmacy and pharmacology.

Effects of fepradinol on rat acute models of vascular permeability and leucocyte migration

Á. Villar, J. Massó, J. Conde, 1994, Agents and Actions.

LRRK2 G2019S and R1441G mutations associated with Parkinson’s disease are common in the Basque Country, but relative prevalence is determined by ethnicity

A. López de Munain, A. Gorostidi, J. Ruiz‐Martinez, 2009, neurogenetics.

Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain)

A. Gorostidi, J. Ruiz‐Martinez, A. L. de Munain, 2010, Movement disorders : official journal of the Movement Disorder Society.